Bassler D, et al. - This trial was formulated in order to gauge the long-term effects of the use of inhaled glucocorticoids on the neurodevelopment of extremely preterm infants for the prevention or treatment of bronchopulmonary dysplasia. No marked variation was illustrated in the rate of neurodevelopmental disability at 2 years between infants who received early inhaled budesonide for the prevention of bronchopulmonary dysplasia and those who received placebo, among surviving extremely preterm infants. However, the mortality rate was discovered to be higher among those who received budesonide.